• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Qiagen launches liquid biopsy tests for lung, prostate cancer

April 13, 2018 By Sarah Faulkner

QiagenQiagen (NYSE:QGEN) today launched two liquid biopsy panels designed to evaluate circulating tumor cells isolated from a patient’s blood samples.

The company’s lung and prostate cancer diagnostic tests will be introduced at the annual meeting of the American Association for Cancer Research in Chicago, according to Qiagen.

“Our AdnaTest liquid biopsy-based portfolio now offers molecular characterization in leading cancers with insights into tumor biology, pathways, relevant biomarkers, cancer progression and even resistance to therapy,” Dr. Thomas Schweins, SVP & head of Qiagen’s life sciences business, said in prepared remarks.

The company’s AdnaTests feature Qiagen’s immunomagnetic cell-selection system, which enriches circulating tumor cells to enable sensitive analysis of genes linked to cancer.

Qiagen’s AdnaTest ProstateCancerPanel kit detects the androgen receptor splice variant 7 in circulating tumor cells isolated from blood samples from prostate tumors. The test assesses potential resistance to drugs for advanced prostate cancer, Qiagen reported, and will be available for researchers to use.

The company’s AdnaTest LungCancer kit uses the specific selection of circulating tumor cells to identify those involved in cancer growth and epithelial-mesenchymaltransition, a marker of resistance to cancer therapy.

“The ability to analyze circulating tumor cells offers potential to expand our understanding of the molecular mechanisms of lung and prostate cancer and advance new approaches to treatment. With the high specificity and sensitivity of the AdnaTest kits, researchers can use liquid biopsies to achieve reliable, accurate characterization of lung and prostate cancer CTCs for interpretation of disease development and metastasis,” Michael Kazinski, senior director & head of sample technologies, added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, Oncology, Wall Street Beat Tagged With: qiagen

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS